Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 5/20 | 0.42 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.40 |
| ▸ | CDA | P32320 | 2/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.37 |
| ▸ | SI | P14410 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FGF1 | P05230 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705107 | 0.87 | OGA (0.41) | OGALGALS8MGAMSIL3MBTL1 | |
| SCHEMBL14747294 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL14856334 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL10236872 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL24872329 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL22251726 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL10032055 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL7098842 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL13756825 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT | |
| SCHEMBL1296044 | 0.74 | LGALS8 (0.56) | LGALS8MGAMSIL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | OGA 294/4885LGALS8 87/4885CDA 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.